Does sleep-disordered breathing worsen insulin resistance and adverse lipid profiles, increasing cardiovascular risk?

Research into sleep-disordered breathing (SDB), particularly obstructive sleep apnea (OSA), underscores its role as a significant driver of metabolic and cardiovascular dysfunction. In older adults, these physiological stressors can be particularly impactful, as age-related changes in vascular health often compound the effects of disordered breathing.

Clinical and effectiveness evidence

Large-scale observational data, including the Wisconsin Sleep Cohort and the Sleep Heart Health Study, demonstrate that SDB is an independent predictor of both metabolic and cardiovascular disease.

• Metabolic Impact: Untreated severe OSA is associated with a significantly higher homeostasis model assessment of insulin resistance (HOMA-IR), with some studies reporting increases of 0.5 to 1.5 units after adjusting for body mass index (BMI).
• Lipid Profiles: Evidence from over 60 studies shows that OSA correlates with a mean increase in triglycerides of approximately 15–20 mg/dL and a decrease in HDL ("good") cholesterol by 2–4 mg/dL.
• Cardiovascular Outcomes: Severe, untreated OSA has been linked to a 3-fold increase in the risk of cardiovascular mortality. Furthermore, patients with type 2 diabetes and comorbid OSA face a 2.28-fold higher risk of major adverse cardiovascular events (MACE) following cardiac procedures.

Mechanistic explanations

The primary driver of these changes is intermittent hypoxia (IH)—the repeated cycle of oxygen desaturation and reoxygenation—and sleep fragmentation.

• Insulin Signaling: IH directly impairs insulin-stimulated glucose uptake in skeletal muscle and compromises pancreatic $\beta$-cell function. It also triggers the sympathetic nervous system, leading to elevated catecholamines that further disrupt glucose metabolism.
• Lipid Metabolism: IH upregulates hepatic lipogenic enzymes, such as stearoyl-CoA desaturase-1 and sterol regulatory element-binding protein-1 (SREBP-1). Simultaneously, it inhibits lipoprotein lipase activity via the protein Angptl4, which prevents the effective clearance of triglyceride-rich lipoproteins from the blood.
• Vascular Damage: These metabolic shifts occur alongside systemic inflammation (elevated TNF-$\alpha$ and IL-6) and oxidative stress, which promote atherosclerosis and endothelial dysfunction.

Bottom line

The claim is strongly supported by science. Sleep-disordered breathing acts as a potent metabolic stressor that worsens insulin resistance and creates a pro-atherogenic lipid profile, significantly elevating the risk of stroke, myocardial infarction, and cardiovascular mortality.